Emerson Electric Co. has announced its fourth quarter and full year results for the fiscal year ending September 30, 2026. The company reported a significant increase in revenue and declared a quarterly cash dividend increase of 7% to $0.595 per share, payable on December 10, 2026. This update is crucial as it reflects the company's ongoing growth and stability in the electronic and other electrical equipment sector.
Emerson Electric Co., incorporated in Missouri, operates primarily in the electronic and other electrical equipment sector, classified under SIC 3600. The company trades on the New York Stock Exchange under the ticker symbol EMR. As a large accelerated filer, Emerson has a history of consistent reporting, with recent filings including an 8-K on October 13, 2026, and another on August 4, 2026.
According to the latest filing, the press release issued on November 4, 2026, highlights the company’s performance metrics and provides insights into its financial condition. The filing states, "On Wednesday, November 4, 2026, a press release was issued regarding the fourth quarter and full year results of Emerson Electric Co." The press release also includes non-GAAP financial measures, which the company believes are useful for evaluating its performance.
This update may affect shareholders and investors looking for insights into Emerson's financial health and future outlook. The company’s positive results may also influence competitors in the electronic and electrical equipment sector, prompting them to evaluate their own performance and strategies.
Looking ahead, Emerson has not specified any immediate next steps in this filing. However, the positive earnings report and dividend increase may lead to further announcements or initiatives in the coming months.
Read Next
BrasilAgro Releases 2026/2027 Harvest Estimates
Peabody Energy reports Q3 results, declares dividend
XPEL Reports Q3 Revenue Growth of 9.9% to $137.8 Million
Spectrum Brands Proposes Acquisition of Helen of Troy for $37/Share
NewAmsterdam Pharma reports Q3 2026 results, highlights progress
Royalty Pharma reports strong Q3 results, raises guidance





